Jin Xi, Zheng Ruo-heng, Li You-ming
Digestive Department, the First Affiliated Hospital, Medical School, Zhejiang University, Zhejiang, China.
Liver Int. 2008 Aug;28(7):990-6. doi: 10.1111/j.1478-3231.2008.01776.x. Epub 2008 May 15.
To present the effect of green tea consumption against liver disease.
Interventional and observational studies both in Western countries and in China and published between the years 1989 and December 2007.
The articles were retrieved from Medline, Embase database, Chinese biomedicine web database and Chinese scientific journal's database using proper MESH headings and assessed by two independent investigators according to established inclusion criteria. The characteristics and outcomes of the chosen articles were displayed for further analysis and the quality of each study was also evaluated according to the widely acknowledged criteria. P<0.05 was defined as statistically significant in all enrolled trials.
Ten qualified studies (eight from China, one from Japan and the other from the USA) with various outcomes such as liver cancer, cirrhosis and fatty liver disease were finally chosen. Among them, study designs differed in that there were four randomized-controlled clinical trials, two cohort, one case-control and three cross-sectional studies. The heterogeneity in the study design, outcomes, cofounders and amount of tea consumption precluded further meta-analysis. Nevertheless, eight studies showed a significant protective role of green tea against various liver diseases as determined by relative risk/odds ratio or P-value and among them, four studies showed a positive correlation between green tea intake and attenuation of liver disease. Moreover, the other two studies also presented the protective tendency of green tea against liver disease.
An increased consumption of green tea may reduce the risk of liver disease.
阐述饮用绿茶对肝脏疾病的影响。
1989年至2007年12月期间在西方国家和中国发表的干预性和观察性研究。
使用适当的医学主题词从Medline、Embase数据库、中国生物医学网络数据库和中国科学期刊数据库中检索文章,并由两名独立研究人员根据既定的纳入标准进行评估。展示所选文章的特征和结果以供进一步分析,并根据广泛认可的标准评估每项研究的质量。在所有纳入试验中,P<0.05被定义为具有统计学意义。
最终选择了10项合格研究(8项来自中国,1项来自日本,1项来自美国),其结果涉及肝癌、肝硬化和脂肪肝等多种疾病。其中,研究设计各不相同,有4项随机对照临床试验、2项队列研究、1项病例对照研究和3项横断面研究。研究设计、结果、混杂因素和绿茶饮用量的异质性使得无法进行进一步的荟萃分析。然而,8项研究表明,根据相对风险/比值比或P值,绿茶对各种肝脏疾病具有显著的保护作用,其中4项研究表明绿茶摄入量与肝脏疾病的减轻呈正相关。此外,另外两项研究也呈现出绿茶对肝脏疾病的保护趋势。
增加绿茶饮用量可能会降低肝脏疾病的风险。